Pamiparib Uses, Dosage, Side Effects and more
Pamiparib is under investigation in clinical trial NCT03933761 (Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy).
| Attribute | Details |
|---|---|
| Trade Name | Pamiparib |
| Generic | Pamiparib |
| Pamiparib Other Names | Pamiparib |
| Type | |
| Formula | C16H15FN4O |
| Weight | Average: 298.321 Monoisotopic: 298.122989282 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
